BPC-157 and TB-500 Dosage Data from Published Research

Searching for bpc 157 tb 500 dosage information returns thousands of forum posts, vendor guides and influencer protocols. Almost none cite primary research. The published literature on both peptides consists entirely of animal studies, and the doses used in those studies were selected for specific species, injury models and administration routes that have no direct human parallel. We compiled every relevant dosing protocol from PubMed below so that researchers can evaluate the actual data rather than rely on secondhand claims. Neither BPC-157 nor TB-500 is approved for human use by the FDA or any other regulatory body.

Published BPC-157 Doses in Animal Studies

BPC-157 has been studied in rats across multiple injury models since the late 1990s. The dose range is narrow: nearly every protocol uses 10 mcg/kg body weight, administered once daily. Some studies also tested a lower dose of 10 ng/kg. The routes vary between intraperitoneal (IP), subcutaneous (SC) and oral (intragastric) administration. Each route produces different pharmacokinetic profiles and cannot be treated as interchangeable.

Subcutaneous and Intraperitoneal Protocols

The majority of BPC-157 injection studies in rats used intraperitoneal delivery at 10 mcg/kg once daily. IP injection places the peptide into the peritoneal cavity, where it is absorbed through the mesenteric circulation into the portal vein. This provides rapid systemic exposure but is a route used exclusively in rodent research. A smaller number of studies used subcutaneous injection, including the Achilles tendon protocol (PMID 21030672) that delivered 10 mcg/kg SC once daily for 14 days. The muscle crush injury study (PMID 20225319) used IP at the same dose and frequency.

A 2022 pharmacokinetic study measured intramuscular bioavailability at 14-19% in rats and 45-51% in dogs. Subcutaneous and intraperitoneal routes were not directly compared, but the data confirms that absorption profiles differ substantially between species even within injection routes. Duration across these protocols ranged from 7 to 28 days, with 14 days being the most common assessment point.

Oral (Intragastric) Protocols

BPC-157 is stable at gastric pH levels of 1-2 for over 24 hours, which makes oral administration feasible in animal experiments. The gastric lesion study (PMID 10672996) administered 10 mcg/kg intragastrically as a single dose before ethanol challenge in rats. The peptide prevented mucosal damage in a dose-dependent fashion. Additional oral studies in colitis and fistula models used similar doses over longer treatment windows.

Oral bioavailability for systemic targets remains poorly characterized. A 2022 PK study found oral bioavailability of 2-7% in rats and 3-5% in dogs, roughly one-tenth of the intramuscular value. For gastrointestinal targets, oral delivery provides high local concentrations at the gut mucosa regardless of systemic absorption. For targets outside the GI tract, the lower systemic exposure raises questions about whether oral doses produce meaningful tissue concentrations at distant injury sites.

Published TB-500 Doses in Animal Studies

TB-500 is a synthetic analog of Thymosin Beta-4 (TB-4), a 43-amino-acid protein involved in actin polymerization and cell migration. The published bpc 157 tb 500 dosage literature shows that TB-4 doses in animal studies are measured in milligrams per kilogram, not micrograms. This is a significant difference from BPC-157, where doses are typically three orders of magnitude lower. The majority of TB-4 research was conducted using pharmaceutical-grade TB-4, not commercial TB-500 products.

The cardiac repair study in mice (PMID 15565145) used 6 mg/kg IP, orders of magnitude higher per kilogram than BPC-157 protocols. The wound healing study (PMID 10469335) used topical application of 5 mcg directly to the wound bed, bypassing systemic absorption entirely. These approaches reflect fundamentally different pharmacological strategies and cannot be averaged into a single "TB-500 dose."

The TB-4 literature is smaller than the BPC-157 literature, and fewer injury models have been tested. The bpc 157 tb 500 dosage question is further complicated by the fact that commercial TB-500 products may differ from the pharmaceutical-grade TB-4 used in published research in terms of sequence fidelity, purity and biological activity.

Why These Doses Do Not Translate Directly to Humans

A persistent misconception is that animal doses can be converted to human doses through simple weight-based arithmetic. A 200 mcg dose in a 250 g rat does not scale proportionally to a 75 kg human. The biology is more complicated, and the FDA has published specific guidance on this topic.

Allometric Scaling: Body Surface Area vs Body Weight

The FDA's Guidance for Industry on Estimating the Maximum Safe Starting Dose describes the body surface area (BSA) method for interspecies dose conversion. This method accounts for differences in metabolic rate, organ blood flow and clearance capacity between species. A rat dose of 10 mcg/kg does not scale linearly to humans. The human equivalent dose (HED) is calculated by dividing the animal dose by a conversion factor of 6.2 for rats or 12.3 for mice.

Even this conversion provides only a rough estimate, not a safe or effective dose. The BSA method was designed for small molecules with well-characterized pharmacokinetics, not for peptides with limited absorption data. For BPC-157 and TB-500 specifically, human pharmacokinetic parameters such as half-life, volume of distribution, protein binding and clearance have never been measured. The HED calculation is a starting point for clinical trial design under medical supervision, not a formula for self-administration.

Route Differences: IP Injection Has No Human Equivalent

Most BPC-157 animal studies used intraperitoneal injection, delivering the compound into the peritoneal cavity. This route is standard in rodent research because it is fast, reliable and does not require anesthesia. IP injection produces rapid absorption through the mesenteric vasculature and portal circulation.

IP injection is not used in human medicine outside narrow clinical contexts such as peritoneal dialysis or intraperitoneal chemotherapy. There is no subcutaneous or intramuscular equivalent that replicates IP pharmacokinetics. Absorption rate, peak plasma concentration and time-to-peak all differ between IP, SC and IM routes. Applying an animal IP dose to a human SC injection without adjustment introduces an unknown and potentially large error.

Bioavailability Unknowns

A 2022 pharmacokinetic study provided the first quantitative bioavailability data for BPC-157 in rats and dogs. Intramuscular bioavailability was 14-19% in rats and 45-51% in dogs. Oral bioavailability was 2-7% in rats and 3-5% in dogs. Bioavailability varies by species and route, sometimes tenfold or more.

Human bioavailability for BPC-157 has never been measured. For TB-500, we found no published pharmacokinetic studies in any species providing quantitative bioavailability values. Without these numbers, calculating what fraction of an administered dose reaches systemic circulation in a human is not possible. Any bpc 157 tb 500 dosage protocol that claims to account for bioavailability in humans is speculating beyond the available evidence.

Reconstitution Arithmetic for Research

Lyophilized peptides must be reconstituted with a suitable solvent before use in laboratory experiments. The arithmetic below applies to standard vial sizes sold by research peptide suppliers. We present these calculations for researchers working with cell culture or animal models who need to prepare solutions at specific concentrations. For an interactive tool, see our reconstitution calculator.

Concentration Calculations for Common Vial Sizes

The formula is straightforward. Divide the total peptide content (converted to micrograms) by the volume of solvent added (in milliliters) to obtain the concentration in mcg/mL. For example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water yields a concentration of 2,500 mcg/mL. The same vial with 1 mL yields 5,000 mcg/mL.

For TB-500, vial sizes are typically larger because the doses used in animal research were in milligrams rather than micrograms. A 5 mg TB-500 vial reconstituted with 1 mL produces a 5,000 mcg/mL solution, the same arithmetic as BPC-157. The difference lies in the volumes drawn per injection in research protocols, reflecting the different dose ranges between the two peptides.

Volume per Injection at Different Concentrations

Once the concentration is known, the volume needed for a specific microgram amount is calculated by dividing the target amount by the concentration. If a researcher needs 250 mcg from a 2,500 mcg/mL solution, the required draw volume is 0.1 mL. On a standard 1 mL insulin syringe with 100 unit markings, 0.1 mL corresponds to the 10-unit mark.